HSIC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HSIC is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has decent fundamental growth, but the technical setup is weak ahead of earnings, analyst sentiment is mixed, and the current pre-market price of 74.95 is still near key support rather than confirming a clear upside breakout. Since there is no AI Stock Picker or SwingMax buy signal today, and the investor is impatient and unwilling to wait for a better entry, the best call is to hold off rather than buy now.
The short-term chart is not constructive. MACD histogram is negative and expanding, which signals downward momentum. RSI_6 at 30.925 is near oversold but not a strong reversal confirmation. Moving averages are converging, suggesting indecision rather than a confirmed uptrend. Price is around 74.95, just above S1 at 73.862 and below the pivot at 77.04, so the stock is trading in a fragile zone. The next resistance is 80.218, while support is 71.898. Overall trend is weak-to-neutral rather than bullish.
["Q4 2025 revenue increased 7.71% YoY", "Net income increased 7.45% YoY and EPS grew 13.33% YoY", "Citi initiated coverage with a Buy rating and $100 target, calling HSIC its top dental pick", "Baird, JPMorgan, and Evercore all have bullish or supportive views with higher targets", "Options positioning is skewed toward calls", "The stock has an upcoming QMAR 2026 earnings release on 2026-05-05 pre-market, which could act as a catalyst"]
["No news in the recent week", "MACD is negative and worsening, indicating weak momentum", "RSI is not confirming a strong rebound", "Morgan Stanley kept an Underweight rating and cut its target to $64", "BTIG called the business mature with only modest growth", "Gross margin declined 0.75% YoY in the latest quarter", "Earnings are due very soon, and the stock is trading below the pivot level"]
In Q4 2025, Henry Schein showed solid top-line and bottom-line growth. Revenue rose to $3.437 billion, up 7.71% YoY, net income increased 7.45% YoY to $101 million, and EPS climbed 13.33% YoY to 0.85. The main weakness was gross margin, which fell to 28.92%, down 0.75% YoY. Overall, the latest quarter season was constructive on growth, but margin pressure remains a concern.
Analyst sentiment is mixed but leaning positive. Recent target increases from Evercore, JPMorgan, Mizuho, UBS, Stifel, and Baird show improving confidence after Q4. Citi is bullish with a Buy and $100 target, while Morgan Stanley is bearish with an Underweight and a lowered target to $64. BTIG is Neutral and views the company as mature with modest growth. Wall Street is split: the bulls like Henry Schein’s leadership position and growth potential, while the bears focus on maturity, competition, and slower dental-market growth.
